Title : Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer.

Pub. Date : 2015 Jun

PMID : 25484141






5 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer. Docetaxel androgen receptor Homo sapiens
2 However, concerns regarding cross-resistance between the taxanes docetaxel and cabazitaxel and these AR-targeted agents have arisen, and the optimal drug treatment sequence is unknown. Docetaxel androgen receptor Homo sapiens
3 Docetaxel inhibited tumor growth, AR nuclear localization, and AR-regulated gene expression in enzalutamide-naive tumors, but did not in enzalutamide-resistant tumors, demonstrating in vivo cross-resistance. Docetaxel androgen receptor Homo sapiens
4 Docetaxel inhibited tumor growth, AR nuclear localization, and AR-regulated gene expression in enzalutamide-naive tumors, but did not in enzalutamide-resistant tumors, demonstrating in vivo cross-resistance. Docetaxel androgen receptor Homo sapiens
5 These findings demonstrate that the AR pathway is able to confer in vivo cross-resistance between enzalutamide and docetaxel, but not cabazitaxel, in CRPC. Docetaxel androgen receptor Homo sapiens